Rise in infectious disease incidence propel antibiotics market growth

Antibiotics Market by Drug Class (Penicillin, Cephalosporin, Aminoglycosides, Tetracycline, Macrolides, Fluoroquinolones, Sulfonamides, and Others), by Drug Origin (Natural, Semi-Synthetic, and Synthetic), by Spectrum (Narrow and Broad Spectrum), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Global Outlook & Forecast Period 2022-2030

According to the deep-dive market assessment study conducted by Growth Plus Reports, the antibiotics market was pegged at ~US$ 40.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of ~4.8% from 2022 to 2030.

The accessibility of antibiotics as over-the-counter medications that can be purchased without a prescription is one of prime aspects that is anticipated to contribute to the market revenue growth. Over the forecast period, the market is expected to be driven by pharmaceutical firms' increased efforts in the discovery of innovative treatments to treat infectious disorders. According to Pew Charitable Trust, around 41 promising compounds were being researched in December 2019 for the treatment of dangerous bacterial infections. 17 of these 41 investigational drugs are either in the phase III of clinical trials or have submitted an NDA for approval, and it is anticipated that they will be on the market within the forecast period. The U.S. FDA approved four new antibiotic medications just in the second half of 2019.

Additionally, it is expected that favourable government legislation, such as the GAIN Act and REVAMP Act, may accelerate the approval process globally. Over the course of the projected period, the introduction of novel antibiotic medications is anticipated to promote market expansion. Due to the rise in infectious disease incidence, there is a noticeable increase in the demand for antibiotics. Another factor driving the market expansion is the high prevalence of infectious disorders like lower respiratory infections, pneumonia, malaria, and tuberculosis.

Government and non-government organisations are being forced to invest in R&D programmes and advance the development of novel antibiotics and helpful regulatory rules to speed up the approval procedure and research funding. For instance, in collaboration with the government, BARDA has offered support to several businesses to help in the process of creating novel treatments for infectious diseases. In the near future, a large number of antibiotic drugs are anticipated to be developed as a result of the collaborations for antibiotic development. To ease the financial burden of the medication development process, pharmaceutical companies are working together to create novel therapies. For instance, Nosopharm and Evotec AG announced their collaboration to develop NOSO-502 in July 2019. It is an innovative first-in-class antibiotic for infections caused by Enterobacteriaceae. Furthermore, to develop novel antibiotics, Forge Therapeutics, Inc. and Basilea Pharmaceutica Ltd. signed a research partnership and licence agreement in April 2019.

Antimicrobial resistance (AMR) has increased among patients due to the continuous use of various antibacterial medications such as broad-spectrum antibiotics, which can be restraining factor for the market growth. The primary factors influencing the emergence of infections with high levels of drug resistance are improper and excessive usage of antibiotics. For instance, each year, more than 2.8 million antibiotic-resistant infections occur in the United States, as reported by the Centres for Disease Control and Prevention (CDC). Moreover, AMR also causes 33,000 fatalities annually and costs the health care systems of EU/EEA nations roughly around US$ 1.1 billion.

North America and Europe dominated the global antibiotics market during forecast period. These markets have a strong regulatory framework and an advanced healthcare infrastructure. One of the main reasons leading to the dominance of North America market is the increase in infectious diseases and high government healthcare spending. The U.S. government is facilitating a number of actions, such as boosting R&D activities for novel medicines to manage infectious diseases and undertaking antibiotic stewardship initiatives.

Asia Pacific is the fastest growing region and anticipated to expand significantly during the projected period. The increased consumption of antibiotics, rise in the prevalence of infectious diseases, and rise in government initiatives to create novel medicines to treat drug-resistant infections are all contributing factors. Additionally, the existence of generic competitors helps the regional market expand. The largest markets in the region for antibiotics are India and China. The main drivers of market expansion in these countries are unrestricted sales and excessive antibiotic use.

Some of the key players operating the market global antibiotics market include Pfizer Inc., GlaxoSmithKline PLC., Sanofi S.A., Abbott Laboratories Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., F. Hoffmann-La Roche Ltd., Allergan Plc., Basilea Pharmaceutica Ltd., and Nabriva Therapeutics plc. Players in the antibiotics market are concentrating on corporate growth, mergers and acquisitions, and cutting-edge technological advancements in order to secure a leading position in the worldwide market.

awards awards key differentiators

Reach Us

enquire@growthplusreports.com

Web –  www.growthplusreports.com